GLP-1 diabetes drugs like Ozempic found effective against migraines

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this widespread impact, many sufferers find current preventive treatments ineffective. Recent scientific exploration points toward an intriguing new option: diabetes drugs known as GLP-1 receptor agonists, including popular medications like Ozempic and Wegovy.

Scientists have long noticed similarities between chronic migraines and another brain condition called idiopathic intracranial hypertension without papilledema (IIWHOP). These two disorders share symptoms such as severe headaches, risk factors like obesity and sleep problems, and elevated levels of a brain chemical called calcitonin gene-related peptide (CGRP). Both conditions often show narrowing in the brain's veins—a sign typically linked to increased pressure within the skull.

These parallels suggest that mild but ongoing changes in brain pressure could trigger migraines, even without obvious signs like optic nerve swelling seen in more severe conditions. Some studies have found that reducing brain pressure through procedures like spinal taps provides sudden relief from migraines, indicating intracranial pressure might play a central role.

A recent pilot study published in the journal Headache, led by neurologist Dr. Simone Braca at the University of Naples Federico II, explored whether GLP-1 agonists, primarily used for diabetes and weight management, could effectively reduce migraines. Over 12 weeks, 26 patients suffering frequent migraines and obesity received a daily dose of the GLP-1 agonist liraglutide. Remarkably, the average number of migraine days per month fell sharply, from about 20 to just nine.

Participants also experienced substantial relief in migraine-related disability. Scores measuring migraine impact dropped by over half. Interestingly, weight loss was minimal during the trial, indicating the improvement wasn't simply due to shedding pounds. Instead, researchers believe the benefit comes from GLP-1 agonists’ ability to lower pressure within the brain.

"This study is very interesting in that the GLP-1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine," Braca said.

GLP-1 agonists, including liraglutide, are typically used to control blood sugar levels in type 2 diabetes and to promote weight loss. These drugs mimic a hormone released after eating, helping to regulate appetite and blood sugar. Yet, their potential reaches beyond these effects.

Research indicates that GLP-1 receptors exist not just in the pancreas but throughout the body, including the brain. Notably, they appear in a brain region called the choroid plexus, crucial for producing cerebrospinal fluid (CSF)—the liquid cushioning the brain and spine. Excessive buildup of this fluid can increase intracranial pressure, squeezing nearby nerves and triggering migraines.

Recent animal studies demonstrated that GLP-1 agonists reduce intracranial pressure significantly. They achieve this by blocking sodium-potassium pumps in the choroid plexus, slowing the rate at which CSF is produced. This effect proved stronger than common treatments for intracranial hypertension like acetazolamide or topiramate. Moreover, the drugs lowered CGRP expression, further helping to calm migraine pathways in the brain.

A small clinical trial confirmed these findings, showing that exenatide, another GLP-1 agonist, significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, greatly improving headache symptoms.

While GLP-1 agonists have become popular for their weight-loss benefits, Braca’s research highlights a broader medical potential. Nearly half the patients in the Naples study reported their headache days reduced by at least 50%. Although some experienced minor side effects like nausea or constipation, none found these problematic enough to discontinue treatment.

"An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine," Braca said. "And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine."

The success of this pilot study paves the way for larger trials. Braca and her colleagues, including lead researcher Dr. Roberto De Simone, plan further investigations involving direct measurements of brain pressure and comparisons among different GLP-1 medications.

Despite current treatments, many people suffering chronic migraines still find relief elusive. New medications that target different biological pathways offer fresh hope.

"There are still a substantial portion of migraine patients that face an unmet need and live with its burden," Braca emphasized. "New drugs targeting other pathways could reassure those patients and give them hope."

GLP-1 agonists are already under study for various health benefits beyond diabetes management, such as reducing heart disease risks and treating neurological conditions like Alzheimer's. If confirmed by larger trials, their effectiveness against migraines could soon join this expanding list.

The potential to manage migraines by lowering brain pressure, independent of weight loss, presents an innovative approach. As scientists unravel the full range of GLP-1 receptor effects, patients suffering frequent, severe migraines might soon benefit from these versatile drugs.

Research findings are available online in the journal Headache.

Note: The article above provided above by The Brighter Side of News.

Like these kind of feel good stories? Get The Brighter Side of News' newsletter.